Similarly, vaccination with autologous DCs pulsed with B-CLL cell lysates in early-stage B-CLL patients has been shown to increase specific CD8+ T cells against leukemia antigens like RHAMM, indicating a shift towards an anti-leukemia response [110]. The gene discussed is CD8A; the disease is B-cell chronic lymphocytic leukemia.